S.A. Mason LLC Cuts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

S.A. Mason LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,407 shares of the medical research company’s stock after selling 59 shares during the period. Amgen comprises about 1.2% of S.A. Mason LLC’s investment portfolio, making the stock its 14th biggest holding. S.A. Mason LLC’s holdings in Amgen were worth $1,845,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Briaud Financial Planning Inc purchased a new stake in Amgen during the third quarter valued at approximately $26,000. OFI Invest Asset Management purchased a new stake in shares of Amgen in the 3rd quarter worth $26,000. Providence Capital Advisors LLC bought a new position in Amgen in the 3rd quarter worth $30,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Amgen in the first quarter worth about $28,000. Finally, Carmel Capital Partners LLC grew its stake in shares of Amgen by 296.6% during the 3rd quarter. Carmel Capital Partners LLC now owns 115 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 86 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $286.30 on Thursday. The firm’s 50 day simple moving average is $290.44 and its 200-day simple moving average is $280.66. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The firm has a market cap of $153.43 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.09 earnings per share. As a group, equities analysts predict that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. UBS Group reduced their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and raised their price target for the company from $264.00 to $320.00 in a report on Thursday, December 21st. The Goldman Sachs Group increased their price objective on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Wednesday, November 29th. Finally, Oppenheimer reissued an “outperform” rating and set a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.